Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to […]
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to […]
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to […]
In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J., Sept. 30, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and […]
Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to […]
